Last reviewed · How we verify
LE Gel
At a glance
| Generic name | LE Gel |
|---|---|
| Also known as | Lotemax |
| Sponsor | Bausch & Lomb Incorporated |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Oxytocin vs Prostaglandins for Labor Induction of Women With an Unfavorable Cervix After 24h of Cervical Ripening (PHASE3)
- Reduction of COVID 19 Transmission to Health Care Professionals (NA)
- LE Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery (PHASE3)
- Loteprednol Etabonate Ophthalmic Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery (PHASE3)
- Loteprednol Ophthalmic Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery (PHASE3)
- Systemic Effects After Local Injection of Platelet-rich Plasma (NA)
- Effect of ANACA3 Slimming Gel on Loss of Abdominal and Thigh Circumferences in Healthy Volunteers (NA)
- Evaluation of the Safety, Systemic Pharmacokinetics, and Tolerability of Single and Repeat Ocular Installations (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LE Gel CI brief — competitive landscape report
- LE Gel updates RSS · CI watch RSS
- Bausch & Lomb Incorporated portfolio CI